Scientists to map tumor changes after cancer combo therapy
NCT ID NCT07482774
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will look at tumor samples from 12 people with esophageal cancer before and after they receive standard chemotherapy plus immunotherapy followed by surgery. Using advanced techniques like single-cell analysis, researchers aim to understand how the tumor environment changes and why some patients respond better. This is an observational study, meaning it does not test a new treatment but gathers information to guide future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could reveal why some patients respond better to chemo-immunotherapy, pointing toward more personalized treatments for esophageal cancer.
- What could go wrong
- This is a very small, early observational study (12 people) that does not test a new treatment. It may not lead to direct patient benefits or apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- AI biomarker may reveal who responds to esophageal cancer immunotherapy
- Can a single Protein's mutations predict esophageal cancer outcomes?
- A sponge you swallow could detect esophageal cancer before it spreads